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Before the construction of this review article, we conducted an elec-
tronic database search through PubMed access to the MEDLINE data-
base on life sciences and biomedical issues (Fig. 1). This search was
inspired by a drastic increase in the number of journal articles on the
subject matter of type 2 diabetes (129,504) in the MEDLINE database;
approximately two-third of the publications (83,071/129,504) were
yielded for the recent 10 years, and more than half of them (49,934/
83,071) were found for the recent 5 years by 31 May 2016. Based on
our research interest, we searched through PubMed/MEDLINE on the
keywords “type 2 diabetes”, “endothelial dysfunction” and “nephropa-
thy” for the recent 5 years, and initially came up with a list of 85 full-
text journal articles (Table S1), of which 45 irrelevant articles were ex-
cluded based on our contextualized interpretations of the titles and ab-
stracts. The remaining 40 journal articles were used as the framework
for constructing this review article, and only research articles (27/40)
were summarized in Table S2 (including research type, subject charac-
teristics and signiﬁcant ﬁndings).Fig. 1. Schematic workﬂow outlining the article selectioThe aim of this review was to summarize some common signaling
pathways of vasodilators, vasoconstrictors and vaso-modulators from
currently proposed endothelium-centered therapies for diabetic ne-
phropathy, and hence highlight somekeypotential cellularmechanisms
for our future therapeutic development. This review also discussed the
potential uses of cutting-edge optoacoustic imaging tools in the real-
time monitoring of renal cortex/pelvis hemodynamics of small labora-
tory animals for preclinical drug trials.
2. Diabetes mellitus
Diabetes encompasses a spectrum of vascular complications in the
micro- (eye, kidney and nerve) and the macro-vasculature (heart and
brain) that are considerably responsible for the recently high morbidity
and mortality. Epidemiological studies demonstrated the global inci-
dence of diabetes had drastically increased from 108 million in 1980
to 422million in 2014, whichwas shown to be obese-associated [1]. Di-
abetes and higher-than-optimal blood glucose also caused 3.7 million
deaths in 2012, of which nearly half of them died before age of 70n process for the construction of this review article.
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diabetes will grow at an unprecedented rate and project to be the 7th
leading cause of mortality in 2030 [2]. The aetiology of type 2 diabetes
mellitus (T2DM) is multifactorial; the causes of the disease are largely
attributed to a complex interplay of genetic and environmental factors.
Previous studies revealed the lifetime risk of a child of affected parents
suffering from T2DMwas 3 to 4 times higher than the general popula-
tion and he/she usually developed diabetes at younger ages [3]. In addi-
tion, behavioral risk factors such as physical inactivity and unhealthy
diets leading to overweight or obese problems usually precede the
onset of prediabetes or overt diabetes [1].
3. High blood glucose-induced endothelial dysfunction
Hyperglycemia represents the pathologic hallmark of diabetes
mellitus, and has been implicated in the onset and progression of endo-
thelial dysfunction. Growing evidence demonstrated hyperglycemia
triggers excessive reactive oxygen species (ROS) production, entailing
oxidative tissue damages [4–6] and hence engaged in the development
and progression of various diseases including cardiovascular diseases
[7], nonalcoholic fatty liver disease [8], renal dysfunction [9], retinopa-
thy [10,11] and cancers [12]. In endothelium, high glucose-stimulated
ROS overproduction was shown to play a crucial role in endothelial
cell senescence [13–16], which is an early sign of vascular complications
in diabetes [17,18]. The production of ROS also uncouples the endothe-
lial isoform of nitric oxide synthase (e-NOS) leading to perturbations to
or reductions innitric oxide (NO) bioavailability,which impair endothe-
lium-dependent vasodilatation [19]. More intriguingly, this e-NOS
uncoupling further augments superoxide radical production, and
hence deteriorates vascular endothelial functionality. The overview of
e-NOS/NO signaling and ROS production was summarized in Fig. 2.
4. Renal pathophysiology in T2DM
The primary function of kidney is to maintain constant plasma
volume, salt concentrations, pH value and waste levels of extracellularFig. 2. In endothelial cells, VEGF signaling modulates e-NOS/NO-mediated vasodilation and RO
membrane-bound receptors (VEGFR2), upon which the PI3K/Akt pathway is activated. The a
increased production of NO. High-glucose-induced ROS overproduction uncouples e-NOS a
ONOO− formation further uncouples e-NOS to augment O2− production, which induces substa
nitric oxide synthase; O2−, superoxide molecules; ONOO−, peroxynitrite molecules; ROS,
endothelial growth factor receptor 2.ﬂuids (plasma and interstitial ﬂuid) inside our body [20,21]. The two
major layers of membrane in the glomerular capsule provide some ﬁl-
tration barriers to shield plasma proteins, of which albumin does nor-
mally enter the ﬁltrate, but only b1% is excreted in the urine. In T2DM,
hyperglycemia-induced defects in renal capillary dilatation, podocyte
loss and oxidative tubular injury to nephron (i.e. loss of reabsorption)
might shed some light on the proposition of albuminuria or proteinuria
as a gold diagnostic measure of chronic kidney disease. Elevated pres-
ence of albumin in the ﬁltrate causes excessive tubular reabsorption
that hence results into inﬂammatory and ﬁbrotic responses, and pro-
gressive loss of renal functions [22]. Numerous recent studies [23–29]
deﬁne the presence of microalbuminuria as an individual persistently
having (≥3 months) (1) urinary albumin excretion ≥30 mg per day,
(2) urinary albumin concentration N 20 μg/L, or (3) urinary albumin to
creatinine ratio of 30–300 mg/g or N3 mg/mmol. However, some dia-
betic patients in advanced kidney disease stages did not clinically pres-
entmicroalbuminuria [30]. A recent experimental study also revealed in
preclinical murine model, neither peak albuminuria nor albuminuria at
4 weeks after adriamycin-induced nephropathywas signiﬁcantly corre-
lated with histologic glomerular scarring [31]. These conﬂicting obser-
vations urge a revolutionary reform of the classical staging system of
chronic kidney disease upon albuminuria into directly mapping im-
paired glomerular ﬁltration to renal dysfunction, which can be mini-
mal-invasively measured by current optoacoustic imaging systems in
a real-time manner (to be discussed).5. Current approaches to therapy for diabetic nephropathy and their
underlying cellular mechanisms
Histologic presence of nodular glomerulosclerosis usually precedes
the disease progression of diabetic nephropathy due to an accumulation
of matrix materials, which contribute to glomerular basement mem-
brane thickening, and hence increase renal blood ﬂow and glomerular
capillary pressure [32]. Since subtle changes in the vascular tone (vaso-
constriction and vasodilation) of the glomerular afferent arterioles (i.e.
microcirculation: b100 μm in diameter) adversely impact the bloodS production. VEGF signaling is induced by the binding of VEGF ligands to their cognate
ctivated p-AktThr308 phosphorylates the serine-1177 residues on e-NOS, and triggers an
nd hence leads to further O2− production, which reacts with NO to form ONOO−. The
ntial oxidative damages and impairs endothelial functions. e-NOS, endothelial isoform of
reactive oxygen species; VEGF, vascular endothelial growth factor; VEGFR2, vascular
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sodilators, vasoconstrictors and vaso-modulatory molecules is critically
important in preserving renal functional integrity. Based on the ﬁndings
from preclinical drug trials in laboratory animals and clinical trials in
T2DM patients, we herein highlighted 4 potential signaling pathways
that govern the vascular endothelial tone as the scientiﬁc basis of cur-
rently proposed drug therapies for diabetic nephropathy: (1) e-NOS/
NO, (2) renin-angiotensin, (3) endothelin-1 (ET-1), and (4) vascular en-
dothelial growth factor (VEGF).
5.1. Endothelial isoform of nitric oxide synthase/nitric oxide signaling
Induced by e-NOS, NO (an endothelium-derived relaxation factor)
serves as a paracrine regulator, which diffuses across into vascular
smooth muscle cells of blood vessels, triggers a cascade of signal trans-
ductions in cytosolic guanylylcyclase/cyclic GMP axis, and subsequently
leads to vascular smooth muscle relaxation [19,33,34]. This regulatory
molecule plays a central role in the regulation of blood ﬂow and blood
pressure that are intricately involved in the development of micro-
and macro-vascular diseases. Recent studies addressed T2DM patients
with chronic renal impairment displayed higher plasma levels of asym-
metric dimethylarginine [35], which is an endogenous inhibitor of NOS.
In addition, a signiﬁcantly lower NOS activitywas observed in T2DMpa-
tients with end-stage renal disease, whom the NOS activity was posi-
tively correlated with serum creatinine clearance (as a measure of
renal function) [36]. Experimental evidence addressed the therapeutic
potentials of 22-oxacalcitriol (a vitamin D3 analog) to improve endo-
thelium-dependent ﬂow-mediated dilatation (FMD) of femoral artery
via augmented e-NOS expression in Sprague-Dawley (SD) fatty rats
(with blood glucose levels N250 mg/dL), and ameliorate e-NOS
uncoupling in high-glucose-treated cultured endothelial cells [37]. Pre-
clinical drug trials of a nitric oxide-potentiating vasodilatory agent,
namely nebivolol, also demonstrated beneﬁcial effects on normalizing
blood pressure, lipid proﬁle, glomerular ﬁltration rate and proteinuria
in Zucker diabetic fatty (ZDF) rats, whom the renal or serum expres-
sions of oxidative stress and inﬂammatory biomarkers including
transforming growth factor-β1 and plasminogen activator inhibitor-1
were down-regulated [38].
5.2. Renin-angiotensin system
Under normal physiologic circumstances, declines in the blood vol-
ume and blood pressure of kidneys trigger juxtaglomerular secretion
of enzyme renin in the formation of angiotensin I from the enzymatic
cleavage of angiotensinogen [20,21]. Angiotensin-converting enzyme
hence converts angiotensin I into angiotensin II by removal of two C-ter-
minal amino acid residues to facilitate vasoconstriction. Experimental
data demonstrated effective blockade of angiotensin-converting en-
zyme was a potential therapeutic target to relieve glomerular
intracapillary pressure and subsequent glomerulosclerotic burden;
combinatorial intervention of ramipril (angiotensin-converting en-
zyme inhibitor) and sitaxsentan (endothelin A-receptor antagonist)
in ZDF rats versus non-diabetic lean controls improved proteinuria
and glomerulosclerosis, and relinquished interstitial nephritis [39].
This observation was concordant with the ﬁndings in a nonrandomized
clinical trial of ramipril in T2DM patients with stage-1 chronic kidney
disease and proteinuria (N0.5 g/day) in improving proteinuria and
FMD of brachial artery [40]. The changes in proteinuria and FMD were
shown to inversely correlate with serum ﬁbroblast growth factor
(FGF)-23 [40], of which increased levels were suggested to be an inde-
pendent predictor of chronic kidney progression in T2DM patients [41].
5.3. Circulating vasoactive peptide: endothelin-1
In the kidney, glomerular endothelial cells, mesangial cells and
podocytes are capable of producing ET-1 [42], which targets endothelinA- and B-receptors (ETA and ETB) of vascular smooth muscle cells and
ETB of endothelial cells to facilitate vasoconstriction of renal vessels
[43]. Within vascular smooth muscle cells, ET-1 receptor activation re-
sults into the orchestration of amultitude of cellular signaling pathways
including MAPK, PI3-K and protein kinase B [44]. Increased circulating
levels of ET-1 are commonly found in T2DM patients [45–47], and
were shown to impair insulin sensitivity in apparently healthy human
subjects in a hyperinsulinemic euglycemic study with co-infusion of
ET-1 precursor and/or ETA- or ETB-receptor blockade [48]. Previous
cross-sectional association studies in T2DM patients demonstrated ele-
vated levels of plasma or urinary ET-1were signiﬁcantly correlatedwith
the presence ofmicroalbuminuria/macroalbuminuria and hypertension
[49–52]. As aforementioned, combined therapy of sitaxsentan (ETA-
receptor antagonist) and ramipril (angiotensin-converting
enzyme inhibitor) in ZDF rats was shown to improve proteinuria,
glomerulosclerosis and interstitial inﬂammation [39]. A recent
double blind, randomized, placebo-controlled clinical trial in T2DM
patients with microalbuminuria (urinary albumin to creatinine
ratio N 3 mg/mmol) also revealed that a dual endothelin receptor
antagonist, namely bosentan, increased reactive hyperaemia index
(as ameasure ofmicrovascular endothelial function) [28]. Experimental
evidence from a recent preclinical study on nebivolol (a nitric oxide-
potentiating vasodilatory agent) in ZDF rats also revealed a signiﬁcant
reduction in serum ET-1 levels [38], indicating a therapeutic crosstalk
between endothelial vasodilators and vasoconstrictors of this agent.
5.4. Vascular endothelial growth factor: an endothelial cell-speciﬁcmitogen
Capillary losses over the progression of chronic kidney disease to
end-stage renal disease are clinically manifested [53]; activation of
VEGF, a potent angiogenic factor, may be another therapeutic target
for alleviating diabetic nephropathy. Several cross-sectional or longitu-
dinal studies in T2DM patients proposed urinary or serum VEGF levels
as independent predictors of the presence of microalbuminuria [25,
54] and chronic kidney disease progression [41]. Genetically-
engineered constitutively-expressing or doxycycline-inducible VEGF-
A165b transgenic mice were shown to resist renal impairments upon
streptozotocin (STZ) administration (a toxic agent targeting insulin-se-
creting beta cells of pancreas) as evidenced by reduced histologic fea-
tures of glomerular abnormalities and preserved morphological
integrity of glomerular endothelial glycocalyx versus non-genetically-
modiﬁed controls [55]. Concurrently, injections of recombinant
human VEGF-A165b into podocytes of another mouse strain or ectopic
expression of VEGF-A165b in cultured primary podocytes and endothe-
lial cells exhibited similar functions in protecting against STZ- or high-
glucose-induced nephrotoxicity and endothelial dysfunction, respec-
tively. A randomized clinical trial of pioglitazone and rosiglitazone
(peroxisome proliferator-activated receptors-gamma agonists) in the
treatment of metabolic syndrome of T2DM patients also accidentally
discovered these agonists might hold additional vascular beneﬁts in
terms of their induction of angiogenesis markers (VEGF, interleukin-8
and angiogenin) [56]. Another possible angiogenic agent, namely thy-
mosin β4 (a thromboxane inhibitor), was largely implicated in diabetic
retinol neovascularization [57], and was also shown to improve histo-
pathologic changes of kidneys in diabetic KK Cg-Ay mice [58]. Paradox-
ically, sulodexide, an antithrombotic drug, was demonstrated to reduce
urinary albumin to creatinine ratio, and suppress renal expressions of
pro-ﬁbrotic molecules and phospho-speciﬁc p38 MAPK possibly
through inhibition of VEGF signaling in Otsuka-Long-Evans-
Tokushima-Fatty T2DM rats [59]. This discrepancy can be well ex-
plained by dose-dependent impacts of VEGF in either being a friend or
foe of diabetic nephropathy; an excessive amount of VEGF was
suggested to be largely detrimental to renal endothelial functions in
STZ-induced diabetic SD rats and diabetic e-NOS gene knockout mice
[60]. Thus, VEGF-targeted intervention could have variable impacts on
diabetic microangiopathy.
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6.1. Oxidative modiﬁcation of microvasculature
The pathologic complexes of diabetic vascular complications are
simply ascribed to uncontrollable blood glucose levels that stimulate
ROS overproduction. In the kidney, excessive ROS production triggers
oxidative damages to glomerular basement membrane, subsequently
leading to loss of ﬁltration surface and impairment in urinary albumin
homeostasis [24]. In endothelial cells, ROS over-production diminishes
NO bioavailability, either through oxidative modiﬁcation of NO (in the
formation of peroxynitrite molecules) or direct interaction with e-NOS
[19]. This e-NOS uncoupling further increases ROS production and
impairs endothelial functionality. Given the angiogenic mechanisms
of VEGF ultimately converge on Akt/e-NOS/NO signaling (Fig. 2), ROS-
induced distortion in e-NOS/NO system (i.e. downstream effectors)
might block the VEGF-stimulated vascular impacts in kidney. In
addition, ROS-induced decline in NO may augment the serum levels of
ET-1 (a vasoconstrictor) [38], which might exacerbate diabetic
nephropathy.
NF-E2-related factor-2 (Nrf2) is recognized as a master guardian of
lifespan that acts through targeting antioxidant response element to
transactivate a multitude of phase II genes including heme oxygenase-
1 (HO-1), whose protein products are tightly involved into ROS detoxi-
ﬁcation and elimination via conjugative stabilizing reactions or by aug-
menting cellular antioxidant capacity [61]. HO-1, which is ubiquitously
expressed in eukaryotes, is an inducible protein in response to oxidative
stress, and catalyzes the degradation of excessive heme into biliverdin
(Fig. 3) [62]. The formation of biliverdin releases carbon monoxide
and ferrous (Fe2+), and in the presence of biliverdin reductase, it is
therefore converted into bilirubin, which scavenges and counteracts
ROS. Abrogation of Nrf2/HO-1 signaling was largely implicated in
acute kidney injury [62], cardiac dysfunction [63], and cerebral ischemia
[64]. Recent pharmacological research in natural products highlighted
many bioactive compounds possess antioxidant properties via Nrf2/
HO-1 signaling. Lycopene (a pharmacologically active compound abun-
dantly found inmany fruits and tomatoes) was shown to protectWistar
rats from cisplatin-induced nephrotoxicity via up-regulating the renal-
cellular presence of nuclear Nrf2 and expression of HO-1 [65].
Curcumin, a powdered rhizome of Curcuma longa Linn, resisted the pro-
gression of cerebral ischemia as evidenced by its effects on the reduction
of neurologic deﬁcits, cerebral infarction and brain volume content via
over-expressing Nrf2 and HO-1 protein in middle cerebral artery-oc-
cluded SD rats [64]. Grounded on the interconnected “Yin/Yang theory”Fig. 3.Heme oxygenase catalyzes the conversion of heme into bilirubin,which counteracts
reactive oxygen species. Heme oxygenase degrades heme into biliverdin through which
carbon monoxide and ferrous (Fe2+) are released. Biliverdin is thus converted into
bilirubin in the presence of biliverdin reductase.of Traditional Chinese medicines, insufﬁcient blood ﬂow (“Yin/Qi”) to
organs will impair their functional integrities (“Yang”) [66]; given (1)
the blood circulation to the kidneys accounts for nearly one-fourth of
the total cardiac output [22], (2) a classical traditional Chinese me-
dicinal prescription of Rheum rhabarbarum and Salvia miltiorrhiza
has been proven to be very efﬁcacious and safe in treating chronic
kidney diseases [67–69], (3) Danshensu, a naturally-occurring
aqueous phenolic extract from Salvia militorrhiza, is pharmacologi-
cally recognized to facilitate blood circulation and get rid of blood
stasis, (4) the predominant biodistribution of Danshensu was
found in the kidney after intraperitoneal injections into mice [70],
and (5) its well-recognized antioxidant roles in cardiac vasculature
via acting on Akt/Nrf2/HO-1 pathway were largely implicated [71–74],
we strongly believe a potential biological role of Danshensu in
alleviating hyperglycemic oxidative stress in renal and endothelial
cellular compartments. However, from our PubMed/MEDLINE
search, no study has been found regarding the therapeutic potentials
of Danshensu in diabetic nephropathy, where this research area
deserves further investigations. The mechanistic crosstalk between
Nrf2/HO-1 and Akt/e-NOS/NO signaling cascades, and the proposed
mechanisms by which Danshensu intercepts hyperglycemic ROS
production were depicted in Fig. 4.6.2. Erasing metabolic memory: an emerging role of epigenetics in diabetic
nephropathy
The existence ofmetabolicmemory is deﬁned as a phenomenon that
the effects of long-term or transient blood glucose changes persist long
in macro- and micro-vasculatures even after attaining glycemic control
in diabetes [75]. This “memory” was initially observed in the Diabetes
Control and Complications Trial conducted by the United States Nation-
al Institute of Diabetes andDigestive and Kidney Diseases that type 1 di-
abetes under intensive glycemic control had a lower incidence of
vascular complications including nephropathy and neuropathy versus
those with conventional therapy (although both groups ultimately
achieved similar levels of glycated hemoglobin (HbA1c; a standard di-
agnostic measure of diabetes mellitus [1])) [76], implicating the effects
of hyperglycemia on inducing vascular complications last long and even
cannot be completely reversed once the vascular endothelial cells had
prior exposure to high blood glucose. Some recent studies highlighted
diabetogenic signals, in particular high blood glucose, stimulated the
phenotypic alterations of vascular endothelial cells without changes in
DNA sequences [77]. This pre-established renal vascular complications
were thus shown to be largely attributed to hyperglycemic epigenetic
histone/DNA modiﬁcations of numerous protein-coding genes [75] in-
cluding forkheadbox proteinO1 (a gluconeogenic gene) [78], osteopon-
tin (a commonly up-regulated gene in diabetic nephropathy) [79],
signal transducer and activator of transcription 1 (a pro-inﬂammatory
molecule) [80], of which most epigenetic methylation/acetylation sig-
natures were highlighted on increased activating histone marks
H3Kac, H3K4me1, H3K4me3 and H3K36me2, and decreased
inactivating histone mark of H3K27me3.
Besides, non-coding RNA-mediated gene silencing or activation is
currently considered as one of the epigenetic mechanisms that regu-
lates endothelial cell phenotypic changes in response to high glucose
in diabetes; hyperglycemia was suggested to alter endothelial
microRNA (miR) and long non-coding RNA (lncRNA) expressions,
where VEGF-targeted miR-320 was up-regulated in myocardial mi-
crovascular endothelial cells of type 2 diabetic Goto-Kakizaki rats
[81], and anti-angiogenic miR-503 [82] and pro-inﬂammatory
lncRNA metastasis-associated lung adenocarcinoma transcript 1
[83] were up-regulated in high-glucose-treated cultured endotheli-
al cells. Since endothelial cell-derived plasma miRs were able to
govern the vascular motile phenotypes of both endothelial and
vascular smooth muscle cells [77], further understanding on their
Fig. 4. Schematic representation of PI3K/Akt, Nrf2/HO-1 and e-NOS/NO signaling crosstalk. Keap1 transiently shuttles between nucleus and cytoplasm in cells, and probes Nrf2 to induce
the ubiquitylation and proteasomal degradation of Nrf2. Once dissociated from Keap1, Nrf2 translocates into the nucleus, and targets consensus ARE regions to trigger transactivation of
HO-1 expression,which therefore impedes ROS production. Danshensuwas proposed to interfere ROS production via activations onNrf2 andHO-1, and increased phosphorylation of Akt.
ARE, antioxidant response element; e-NOS, endothelial isoform of nitric oxide synthase;HO-1, heme oxygenase-1; Keap1, Kelch-like ECH-associated protein 1;Nrf2, NF-E2-related factor-2;
O2−, superoxide molecules; ONOO−, peroxynitrite molecules; ROS, reactive oxygen species.
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target(s) for therapeutics.
7. Real-time optoacoustic vascular imaging of renal cortex/pelvis of
small experimental animals
Since many ﬁndings from experimental studies on new drug candi-
dates in tissue cultured cells turn out to be invalid in preclinical animal
models and human clinical trials [27,84], macroscopic optic imaging
attempted to offer an avenue for characterizing pharmacodynamics
and biodistributions of small drug molecules. Nevertheless, a very long
image acquisition time usually complicated the use of conventional
small-animal optoacoustic techniques for preclinical drug trials [85].
This problem is largely attributed to the fact that large-scale image aver-
aging was required to compensate the very weak signals acquired from
low penetration power. In addition, these systems are not appropriate
for real-time whole-body imaging of small experimental animals,
hence most probably failing to capture some critical moments of rele-
vant physiologic parameters.
Recent breakthrough in the dimension ofmacroscopic optic imaging
has brought a variety of leading advantages from basic biology to pre-
clinical practice; multispectral optoacoustic tomography (MSOT) hasafforded very rapid high-radiant-power interlock system in the near-
infrared region passing through several millimeters into centimeters
of tissue to generate ultrasound signals, which substantially surpass
light-scattering interference of tissue in the formation of high-contrast
multiple spatial images [86]. It also carries high-throughput capability
for quantitative differentiation of target tissues in video-rate mode to
avoid image acquisition delay over time. Through multispectral
unmixing algorithms, this system can pinpoint some regions of interest
in the target tissues and allow multiple detections of signals at various
wavelengths simultaneously, thereby accurately decomposing the
biodistribution of relevant intrinsic and exogenous chromophores
fromnon-speciﬁc background noises.With function-speciﬁc exogenous
chromophores (e.g. indocyanine green, IRDye 800CW carboxylate,
MMPSense 680), functional characterizations of drug candidates on tis-
sues of interest will be optimized. Previous studies demonstrated FITC-
sinistrin and IRDye 800CW carboxylate clearancewere shown to signif-
icantly feature glomerular damage in adriamycin-administered mice
[31]. MSOT was also able to detect atherosclerotic activity with aids of
a protease-activatable ﬂuorescent probe (MMPSense 680), and the con-
clusions drawn were in line with that from standard epi-ﬂuorescent
cryosection imaging, in situ zymography and immunohistochemistry
of elevated activity of various matrix metalloproteases (MMPs) [87].
127W.K.C. Leung et al. / Life Sciences 166 (2016) 121–130Besides, MSOT was capable of demonstrating a real-time tumoral ex-
pression and inhibition of MMP activities in a subcutaneous tumor-
bearing mouse model [88].
Using the same imaging protocol that was validated and adopted in
Scarfe group's study on SCID mice [31], our team was able to demon-
strate the renal cortex/pelvis hemodynamics using isoﬂurane- anes-
thetic diabetic/obese db/db C57BL/6 mouse model [This preliminary
study was approved by the Animal Subjects Ethics Sub-committee of
the Hong Kong Polytechnic University (15-16/14-HTI-R-OTHERS)].
The two kinetic curves against time (min) displayed the near-infrared
ﬂuorescent IRDye 800CWcarboxylate (10 nmol, intravenously injected)
transition from renal cortex into pelvis, and the timedifference between
the signal peaks of the two curves (TMAX-2− TMAX-1) was used to com-
pute kidney perfusion time (as a measure of glomerular ﬁltration rate)
(Fig. 5). Given the drug candidates potentiate renoprotective functions
against diabetogenic nephrotoxicity, the time difference between
TMAX-1 and TMAX-2 will be shortened compared with non-treated
group. Fig. 6 illustrated the video-rate, real-time MSOT monitoring of
kidney perfusion of the diabetic/obese db/dbmouse.
Due to highly vascularized infrastructure of kidneys, the speciﬁcity and
sensitivity of MSOT open a novel avenue for studies of renal-kinetic drugFig. 5. Cross-sectional optoacoustic image of a diabetic/obese db/db C57BL/6 mouse. (a) The c
position. (b) The optoacoustic images illustrated the near-infrared ﬂuorescent IRDye 800C
selected (red, renal cortex; blue, renal pelvis). (c) The two kinetic curves of the selected regio
two time points with maximal signals (TMAX-1 and TMAX-2). The kidney perfusion time was thucandidates in small experimental animals. Without sacriﬁcing the ani-
mals as the endpoint, the minimally invasive characteristic of MSOT
also anticipates the signiﬁcance of experimental animal welfare and
ethics (replacement, reduction and reﬁnement) to pilot drug efﬁcacy
and safety in laboratory animals prior to conducting sizable clinical
trials in human.
8. Conclusion
In summary, the published journal articles for the recent 5 years
demonstrated a concurrent therapeutic direction for diabetic nephrop-
athy towards targeting vasodilators, vasoconstrictors and vaso-modula-
tory molecules, where the signaling aberrations underlying the
pathogenesis of vascular endothelial dysfunction lay the groundwork
for the current therapeutic designs. The hyperglycemic induction of ox-
idative stress and epigenetic changes in kidneys offers new insight of
our future drug studies and experimental trials, and our proposed
optoacoustic imaging system provides feasibility of highly penetrating
into target organs and processing extremely high-contrast vascular im-
ages of preclinical animal models for experimental drug trials that the
data are valid and reliably re-produced.ross-sectional optoacoustic image aligned with the corresponding cryoslice at the same
W carboxylate transition from renal cortex to pelvis, and the regions of interest were
ns demonstrated the ﬂuorescent signal intensities against time (min) and also indicated
s computed by subtracting TMAX-1 from TMAX-2 (arrow).
Fig. 6. Video-rate optoacoustic imaging of IRDye 800CW carboxylate perfusion from renal cortex into pelvis of a diabetic/obese db/db C57BL/6 mouse at various times.
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